A novel recombinant antibody specific to full-length stromal derived factor-1 for potential application in biomarker studies.
<h4>Background</h4>Stromal derived factor-1α (SDF-1α/CXCL12) is a chemokine that is up-regulated in diseases characterised by tissue hypoxia, including myocardial infarction, ischaemic cardiomyopathy and remote ischaemic conditioning (RIC), a technique of cyclical, non-injurious ischaemi...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2017-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0174447&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850133397071986688 |
|---|---|
| author | Daniel I Bromage Stasa Taferner Mahesh Pillai Derek M Yellon Sean M Davidson |
| author_facet | Daniel I Bromage Stasa Taferner Mahesh Pillai Derek M Yellon Sean M Davidson |
| author_sort | Daniel I Bromage |
| collection | DOAJ |
| description | <h4>Background</h4>Stromal derived factor-1α (SDF-1α/CXCL12) is a chemokine that is up-regulated in diseases characterised by tissue hypoxia, including myocardial infarction, ischaemic cardiomyopathy and remote ischaemic conditioning (RIC), a technique of cyclical, non-injurious ischaemia applied remote from the heart that protects the heat from lethal ischaemia-reperfusion injury. Accordingly, there is considerable interest in SDF-1α as a potential biomarker of such conditions. However, SDF-1α is rapidly degraded and inactivated by dipeptidyl peptidase 4 and other peptidases, and the kinetics of intact SDF-1α remain unknown.<h4>Methods & results</h4>To facilitate investigation of full-length SDF-1α we established an ELISA using a novel recombinant human antibody we developed called HCI.SDF1. HCI.SDF1 is specific to the N-terminal sequence of all isoforms of SDF-1 and has a comparable KD to commercially available antibodies. Together with a detection antibody specific to the α-isoform, HCI.SDF1 was used to specifically quantify full-length SDF-1α in blood for the first time. Using RIC applied to the hind limb of Sprague-Dawley rats or the arms of healthy human volunteers, we demonstrate an increase in SDF-1α using a commercially available antibody, as previously reported, but an unexpected decrease in full-length SDF-1α after RIC in both species.<h4>Conclusions</h4>We report for the first time the development of a novel recombinant antibody specific to full-length SDF-1. Applied to RIC, we demonstrate a significant decrease in SDF-1α that is at odds with the literature and suggests a need to investigate the kinetics of full-length SDF-1α in conditions characterised by tissue hypoxia. |
| format | Article |
| id | doaj-art-234f7f2bdbab42f3a301b0562cf3d9c3 |
| institution | OA Journals |
| issn | 1932-6203 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-234f7f2bdbab42f3a301b0562cf3d9c32025-08-20T02:31:58ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01124e017444710.1371/journal.pone.0174447A novel recombinant antibody specific to full-length stromal derived factor-1 for potential application in biomarker studies.Daniel I BromageStasa TafernerMahesh PillaiDerek M YellonSean M Davidson<h4>Background</h4>Stromal derived factor-1α (SDF-1α/CXCL12) is a chemokine that is up-regulated in diseases characterised by tissue hypoxia, including myocardial infarction, ischaemic cardiomyopathy and remote ischaemic conditioning (RIC), a technique of cyclical, non-injurious ischaemia applied remote from the heart that protects the heat from lethal ischaemia-reperfusion injury. Accordingly, there is considerable interest in SDF-1α as a potential biomarker of such conditions. However, SDF-1α is rapidly degraded and inactivated by dipeptidyl peptidase 4 and other peptidases, and the kinetics of intact SDF-1α remain unknown.<h4>Methods & results</h4>To facilitate investigation of full-length SDF-1α we established an ELISA using a novel recombinant human antibody we developed called HCI.SDF1. HCI.SDF1 is specific to the N-terminal sequence of all isoforms of SDF-1 and has a comparable KD to commercially available antibodies. Together with a detection antibody specific to the α-isoform, HCI.SDF1 was used to specifically quantify full-length SDF-1α in blood for the first time. Using RIC applied to the hind limb of Sprague-Dawley rats or the arms of healthy human volunteers, we demonstrate an increase in SDF-1α using a commercially available antibody, as previously reported, but an unexpected decrease in full-length SDF-1α after RIC in both species.<h4>Conclusions</h4>We report for the first time the development of a novel recombinant antibody specific to full-length SDF-1. Applied to RIC, we demonstrate a significant decrease in SDF-1α that is at odds with the literature and suggests a need to investigate the kinetics of full-length SDF-1α in conditions characterised by tissue hypoxia.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0174447&type=printable |
| spellingShingle | Daniel I Bromage Stasa Taferner Mahesh Pillai Derek M Yellon Sean M Davidson A novel recombinant antibody specific to full-length stromal derived factor-1 for potential application in biomarker studies. PLoS ONE |
| title | A novel recombinant antibody specific to full-length stromal derived factor-1 for potential application in biomarker studies. |
| title_full | A novel recombinant antibody specific to full-length stromal derived factor-1 for potential application in biomarker studies. |
| title_fullStr | A novel recombinant antibody specific to full-length stromal derived factor-1 for potential application in biomarker studies. |
| title_full_unstemmed | A novel recombinant antibody specific to full-length stromal derived factor-1 for potential application in biomarker studies. |
| title_short | A novel recombinant antibody specific to full-length stromal derived factor-1 for potential application in biomarker studies. |
| title_sort | novel recombinant antibody specific to full length stromal derived factor 1 for potential application in biomarker studies |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0174447&type=printable |
| work_keys_str_mv | AT danielibromage anovelrecombinantantibodyspecifictofulllengthstromalderivedfactor1forpotentialapplicationinbiomarkerstudies AT stasataferner anovelrecombinantantibodyspecifictofulllengthstromalderivedfactor1forpotentialapplicationinbiomarkerstudies AT maheshpillai anovelrecombinantantibodyspecifictofulllengthstromalderivedfactor1forpotentialapplicationinbiomarkerstudies AT derekmyellon anovelrecombinantantibodyspecifictofulllengthstromalderivedfactor1forpotentialapplicationinbiomarkerstudies AT seanmdavidson anovelrecombinantantibodyspecifictofulllengthstromalderivedfactor1forpotentialapplicationinbiomarkerstudies AT danielibromage novelrecombinantantibodyspecifictofulllengthstromalderivedfactor1forpotentialapplicationinbiomarkerstudies AT stasataferner novelrecombinantantibodyspecifictofulllengthstromalderivedfactor1forpotentialapplicationinbiomarkerstudies AT maheshpillai novelrecombinantantibodyspecifictofulllengthstromalderivedfactor1forpotentialapplicationinbiomarkerstudies AT derekmyellon novelrecombinantantibodyspecifictofulllengthstromalderivedfactor1forpotentialapplicationinbiomarkerstudies AT seanmdavidson novelrecombinantantibodyspecifictofulllengthstromalderivedfactor1forpotentialapplicationinbiomarkerstudies |